ISSN: 2329-9053

Журнал молекулярной фармацевтики и исследований органических процессов

Открытый доступ

Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.

 

Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей

Абстрактный

Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment

Toshimori Beall

p>The COVID-19 pandemic has created an urgent need for effective treatments against the SARS-CoV-2 virus. Drug repurposing, which involves identifying new therapeutic uses for existing drugs, has emerged as a valuable approach to expedite the discovery of potential COVID-19 treatments. This article provides an overview of drug repurposing, highlights promising repurposed drugs, and discusses novel drug targets for COVID-19 treatment. Notable repurposed drugs include remdesivir, dexamethasone, tocilizumab, and ivermectin. Additionally, researchers are exploring novel drug targets such as the spike protein, proteases, RNA polymerase, and immunomodulatory pathways. However, further clinical trials and research is required to establish the efficacy and safety of these drugs and targets. Drug repurposing and the exploration of novel drug targets offer potential solutions to combat the COVID-19 pandemic and enhance global healthcare resilience.